GlassScriptPhysician profile
Vidal Manuel Despradel
NPI 1689632697
$5,808.37
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $1,061 · 2021: $1,575 · 2022: $871 · 2023: $1,075 · 2024: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $887.20 | 2019-2023 | Speedicath |
| Teleflex LLC | $712.55 | 2020-2024 | Urolift |
| Boston Scientific Corporation | $545.59 | 2019-2024 | Lithovue, Advance Xp, Spaceoar Vue System - 10ml |
| Astellas Pharma US INC | $522.54 | 2019-2023 | Myrbetriq |
| Janssen Biotech, INC. | $396.54 | 2019-2024 | Erleada, Akeega |
| Neotract INC. | $258.17 | 2020 | |
| Sumitomo Pharma America, INC. | $185.23 | 2023-2024 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $181.20 | 2019-2023 | |
| Myriad Genetic Laboratories, INC. | $177.55 | 2023-2024 | Prolaris |
| Merck Sharp & Dohme LLC | $137.60 | 2020-2024 | Keytruda |
| Amgen INC. | $134.27 | 2019-2021 | |
| Foundation Medicine, INC. | $127.53 | 2021 | |
| Abbvie INC. | $126.55 | 2019-2024 | Lupron Depot |
| Pfizer INC. | $120.97 | 2022-2024 | |
| Antares Pharma, INC. | $118.26 | 2021-2023 | Tlando, Nocdurna, Xyosted |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidal Despradel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.